NCT02727608View on ClinicalTrials.gov

Complement Inhibitor Eculizumab in Clinical Islet Transplantation

PHASE2CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

May 15, 2016

Primary Completion Date

May 31, 2018

Study Completion Date

June 30, 2018

Conditions
Diabetes Mellitus
Interventions
DRUG

Eculizumab

Intravenous infusion (1200 mg) over 35 minutes. Consecutive infusions (900 mg) on Days 1, 7 and 14.

Trial Locations (1)

752 37

Dept of Surgical Sciences, Section of Transplantation Surgery, University Hospital, Uppsala

All Listed Sponsors
lead

Uppsala University

OTHER

NCT02727608 - Complement Inhibitor Eculizumab in Clinical Islet Transplantation | Biotech Hunter | Biotech Hunter